Edge Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Edge Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20	Closed	-$2K	–	187
2021 Q4	$2K	Hold	20	–	–	﹤0.01%	415
2021 Q3	$2K	Hold	20	–	–	﹤0.01%	426
2021 Q2	$3K	Hold	20	–	–	﹤0.01%	367
2021 Q1	$2K	Hold	20	–	–	﹤0.01%	374
2020 Q4	$3K	Hold	20	–	–	﹤0.01%	314
2020 Q3	$2K	Sell	20 -250	-93%	-$22.2K	﹤0.01%	386
2020 Q2	$20K	Hold	270	–	–	﹤0.01%	362
2020 Q1	$11K	Sell	270 -147,799	-100%	-$7.63M	﹤0.01%	384
2019 Q4	$2.4M	Buy	148,069 +148,049	+740,245%	+$8.08M	0.48%	47
2019 Q3	$0	Buy	+20	New	+$956	﹤0.01%	611

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Edge Wealth Management's CRSP Position: Q1 2022 in Review

Edge Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 20 shares — an estimated $2K sold.

Edge Wealth Management first reported a position in CRSP in Q3 2019 and held it in 10 quarters. The position peaked at $2.4M in Q4 2019. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Edge Wealth Management reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Edge Wealth Management sold 20 CRISPR Therapeutics shares in Q1 2022, an estimated $2K.
Edge Wealth Management first reported a position in CRISPR Therapeutics in Q3 2019 and held it in 10 quarters.
Edge Wealth Management's CRISPR Therapeutics position peaked at $2.4M in Q4 2019.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Edge Wealth Management's 13F filing for Q1 2022, filed 14 Apr 2022.